PMID- 9657468
OWN - NLM
STAT- MEDLINE
DCOM- 19980715
LR  - 20220317
IS  - 0009-7322 (Print)
IS  - 0009-7322 (Linking)
VI  - 97
IP  - 25
DP  - 1998 Jun 30
TI  - Effects of tumor necrosis factor gene polymorphisms on patients with congestive 
      heart failure. VEST Investigators for TNF Genotype Analysis. Vesnarinone Survival 
      Trial.
PG  - 2499-501
AB  - BACKGROUND: Tumor necrosis factor-alpha (TNF-alpha) is known to be elevated in 
      patients with congestive heart failure (CHF). Two biallelic polymorphisms have 
      been identified in the TNF gene locus: one in the promoter region of TNF-alpha 
      (TNFA1/2), and the other in the first intron of TNF-beta (TNFB1/2). Both TNFA2 
      and TNFB2 alleles are associated with high TNF-alpha production in vitro and 
      susceptibility to inflammatory diseases. Given the importance of TNF-alpha in the 
      pathogenesis of CHF, we studied the prevalence of TNF gene polymorphisms in CHF 
      patients and the correlation of genotypes to in vivo TNF-alpha levels. METHODS 
      AND RESULTS: TNFA and TNFB genotypes were determined by the polymerase chain 
      reaction-restriction fragment length polymorphism technique. There were no 
      differences in the TNF allele frequencies between CHF (n=229; TNFA1/2=0.84/0.16, 
      TNFB1/2=0.33/0.67) and control subjects (n=139; TNFA1/2=0.84/0.16, 
      TNFB1/2=0.32/0.68). In 211 patients with CHF, circulating levels of TNF-alpha and 
      the soluble receptors type I and type II were measured by ELISA: 6.18+/-3.59 
      pg/mL, 1768+/-761 pg/mL, and 4484+/-1750 pg/mL, respectively. There were no 
      correlations between TNFA or TNFB genotypes and circulating levels of TNF-alpha 
      or its soluble receptors in the CHF patients. CONCLUSIONS: Despite their 
      association with other inflammatory diseases, neither TNFA nor TNFB polymorphisms 
      are related to the presence of CHF or the elevation of circulating TNF-alpha. 
      Thus, other factors may be more important in determining the circulating levels 
      of TNF-alpha in CHF.
FAU - Kubota, T
AU  - Kubota T
AD  - Division of Cardiology, University of Pittsburgh Medical Center, PA 15213, USA.
FAU - McNamara, D M
AU  - McNamara DM
FAU - Wang, J J
AU  - Wang JJ
FAU - Trost, M
AU  - Trost M
FAU - McTiernan, C F
AU  - McTiernan CF
FAU - Mann, D L
AU  - Mann DL
FAU - Feldman, A M
AU  - Feldman AM
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 0 (DNA Primers)
RN  - 0 (Lymphotoxin-alpha)
RN  - 0 (Tumor Necrosis Factor-alpha)
SB  - IM
MH  - Adult
MH  - Case-Control Studies
MH  - DNA Primers
MH  - Disease Susceptibility
MH  - Female
MH  - Genotype
MH  - Heart Failure/*blood/*genetics
MH  - Humans
MH  - Lymphotoxin-alpha/blood/genetics
MH  - Male
MH  - Middle Aged
MH  - *Polymorphism, Genetic
MH  - Severity of Illness Index
MH  - Tumor Necrosis Factor-alpha/*genetics/*metabolism
EDAT- 1998/07/10 00:00
MHDA- 1998/07/10 00:01
CRDT- 1998/07/10 00:00
PHST- 1998/07/10 00:00 [pubmed]
PHST- 1998/07/10 00:01 [medline]
PHST- 1998/07/10 00:00 [entrez]
AID - 10.1161/01.cir.97.25.2499 [doi]
PST - ppublish
SO  - Circulation. 1998 Jun 30;97(25):2499-501. doi: 10.1161/01.cir.97.25.2499.